A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus
Principal Investigator
Jonathan Feddock, MD
Status
Terminated
Date Opened To Accrual
February 25 2008
Date Closed to Accrual
August 13 2020
Date of Study Termination
April 25 2024
Disease Site
Gynecologic [GY]
Uterine Corpus
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina.
Patient Population
Pelvic radiation therapy with concurrent cisplatin or pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina.
Target Accrual
154
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.